RxDoctor Payments Data

William Stevens

Marina del Rey, CANPI 1689709008

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $842,580 of the $910,722 with a category attached, or 92.5%. AbbVie accounts for 97.2% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2020 at $245,871 and has fallen 98.8% since, to $3,017 in 2025.

$910,722in general payments, 2019–2025

Across 222 payments — averaging $4102.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$885K
  • Solta Medical, A Division Of Bausch Health US, LLC$21K
  • Revance Therapeutics, Inc.$3K
  • Merz North America, Inc.$999
  • Sientra, Inc.$586
  • Galderma Laboratories, L.p.$432
  • plus $220 from 4 others
$2,075in research payments, 2019–2025

Across 4 payments — averaging $518.75 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AbbVie$1K
  • Sientra, Inc.$1K

What the payments were for

  • Consulting fees$842,58093%
  • Speaking & faculty fees$60,0007%
  • Travel & lodging$1,7430%
  • Food & beverage$6,3991%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Where these figures come from

Is this you, or does something look wrong? →